Stockscreener 앱 받기
45.80
6.19%
-3.02
시간 외 거래:
46.69
0.89
+1.94%
전일 마감가:
$48.82
열려 있는:
$48.93
하루 거래량:
919.72K
Relative Volume:
1.68
시가총액:
$2.14B
수익:
-
순이익/손실:
$-38.99M
주가수익비율:
-15.28
EPS:
-2.9966
순현금흐름:
$-24.94M
1주 성능:
+1.76%
1개월 성능:
-5.61%
6개월 성능:
-3.11%
1년 성능:
-6.89%
1일 변동 폭
$45.09
$49.80
1주일 범위
$43.06
$49.80
52주 변동 폭
$36.61
$60.92
Soleno Therapeutics Inc Stock (SLNO) Company Profile
명칭
Soleno Therapeutics Inc
전화
650-213-8444
주소
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
SLNO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
45.80 | 2.14B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-02 | 재확인 | Robert W. Baird | Outperform |
| 2024-12-02 | 재확인 | Stifel | Buy |
| 2024-09-03 | 개시 | H.C. Wainwright | Buy |
| 2024-05-10 | 개시 | Robert W. Baird | Outperform |
| 2024-02-05 | 개시 | Piper Sandler | Overweight |
| 2024-01-23 | 개시 | Stifel | Buy |
| 2023-11-21 | 재개 | Guggenheim | Buy |
| 2020-09-29 | 개시 | Guggenheim | Buy |
| 2020-01-10 | 개시 | Craig Hallum | Buy |
| 2019-12-23 | 개시 | Oppenheimer | Outperform |
| 2018-02-13 | 재확인 | Maxim Group | Buy |
모두보기
Soleno Therapeutics Inc 주식(SLNO)의 최신 뉴스
Exploring US High Growth Tech Stocks In March 2025 - Simply Wall St
Cantor Fitzgerald maintains $67 target on Soleno Therapeutics stock - Investing.com
(SLNO) Trading Signals - Stock Traders Daily
Soleno Therapeutics Reports 2024 Financial Results and Strategic Progress - MSN
Soleno Therapeutics (NASDAQ:SLNO) Releases Earnings Results, Misses Estimates By $0.41 EPS - MarketBeat
Soleno Therapeutics (SLNO) to Release Quarterly Earnings on Wednesday - MarketBeat
SOLENO THERAPEUTICS INC SEC 10-K Report - TradingView
Soleno Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results - TradingView
Can Soleno's $318M War Chest Power DCCR Through FDA Priority Review for Rare Disease Treatment? - StockTitan
Major Public Health Interest? Scholar, Insmed & Soleno Ask EMA To Fast-Track Their Products - Pink Sheet
TimesSquare Capital Management LLC Buys Shares of 339,774 Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight - GlobeNewswire Inc.
Allspring Global Investments Holdings LLC Sells 13,396 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Stock Holdings Lowered by Allspring Global Investments Holdings LLC - MarketBeat
(SLNO) Long Term Investment Analysis - Stock Traders Daily
Soleno Therapeutics (NASDAQ:SLNO) Stock Passes Above Fifty Day Moving Average – Should You Sell? - Defense World
Soleno Therapeutics (NASDAQ:SLNO) Stock Passes Above Fifty Day Moving AverageShould You Sell? - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Brokerages Set Soleno Therapeutics, Inc. (NASDAQ:SLNO) Price Target at $71.20 - Defense World
What is Lifesci Capital's Estimate for SLNO Q4 Earnings? - MarketBeat
Soleno Therapeutics (NASDAQ:SLNO) Upgraded by Lifesci Capital to Strong-Buy Rating - MarketBeat
Trend Tracker for (SLNO) - Stock Traders Daily
Equities Analysts Set Expectations for SLNO Q4 Earnings - Defense World
SLNO Stock Sees Surge of Approximately 3.38% in Last Five Days - Knox Daily
What was Soleno Therapeutics Inc (SLNO)’s performance in the last session? - US Post News
Lifesci Capital Upgrades Soleno Therapeutics (NASDAQ:SLNO) to “Strong-Buy” - Defense World
BlackRock, Inc. Reduces Stake in Soleno Therapeutics Inc - GuruFocus.com
Moody Aldrich Partners LLC Purchases New Shares in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics to Participate in Upcoming February Investor Conferences - The Manila Times
Soleno Therapeutics, Inc. to Participate in February Investor Conferences - Nasdaq
Rare Disease Pioneer Soleno Takes Center Stage at Major Healthcare Investment Forums - StockTitan
(SLNO) Investment Report - Stock Traders Daily
Soleno Therapeutics executives receive pay raises and bonuses - MSN
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Stock Holdings Lifted by JPMorgan Chase & Co. - Defense World
Soleno Therapeutics executives receive pay raises and bonuses By Investing.com - Investing.com Nigeria
Soleno Therapeutics Enhances Executive Compensation Structure - TipRanks
Brokers Set Expectations for SLNO FY2025 Earnings - Defense World
Equities Analysts Issue Forecasts for SLNO FY2025 Earnings - MarketBeat
High Growth Tech Stocks to Watch in January 2025 - Simply Wall St
Soleno Therapeutics Breaks Above 200-Day Moving AverageBullish for SLNO - Nasdaq
Soleno Therapeutics (NASDAQ:SLNO) Trading 8.6% HigherHere's What Happened - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives $74.83 Consensus PT from Brokerages - MarketBeat
Soleno Therapeutics Inc (SLNO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Soleno Therapeutics Inc 주식 (SLNO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Yen Kristen | SEE REMARKS |
Jan 03 '25 |
Sale |
46.18 |
2,340 |
108,053 |
76,605 |
| Mackaness James H | CHIEF FINANCIAL OFFICER |
Jan 02 '25 |
Sale |
45.41 |
4,083 |
185,406 |
115,089 |
| Mackaness James H | CHIEF FINANCIAL OFFICER |
Jan 03 '25 |
Sale |
46.18 |
3,791 |
175,055 |
111,298 |
| Hirano Patricia C | SEE REMARKS |
Jan 02 '25 |
Sale |
45.41 |
1,571 |
71,338 |
107,361 |
| Hirano Patricia C | SEE REMARKS |
Jan 03 '25 |
Sale |
46.18 |
1,459 |
67,371 |
105,902 |
| Anish Bhatnagar | CHIEF EXECUTIVE OFFICER |
Jan 02 '25 |
Sale |
45.41 |
10,937 |
496,640 |
708,616 |
| Anish Bhatnagar | CHIEF EXECUTIVE OFFICER |
Jan 03 '25 |
Sale |
46.18 |
10,154 |
468,875 |
698,462 |
6.45%
1.23%
자본화:
|
볼륨(24시간):